Form 6-K TEVA PHARMACEUTICAL INDU For: Jan 05
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
Teva Pharmaceutical Industries Ltd. |
||||
(Translation of registrants name into English) | ||||
Israel | ||||
(Jurisdiction of incorporation or organization) | ||||
5 Basel Street, P.O. Box 3190 Petach Tikva 4951033 Israel |
||||
(Address of principal executive office) |
||||
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F: [x] Form 20-F [ ] Form 40-F | ||||
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): [ ] | ||||
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): [ ] | ||||
Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934: [ ] Yes [x] No | ||||
If "Yes" is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): n/a |
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. |
Teva Pharmaceutical Industries Ltd. | ||
Date: 01/05/2017 | By: |
Eyal Desheh |
Name: | Eyal Desheh | |
Title: | Group EVP & CFO | |
Exhibit No. | Description | |
|
|
|
99.1 | Teva to Host 2017 Business Outlook Conference Call and Webcast on January 6, 2017 | |
Teva to Host 2017 Business Outlook Conference Call and Webcast on January 6, 2017
Jerusalem, January 5, 2017 - Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) announced today that it will host a conference call and live webcast on Friday, January 6, 2017 at 8:00 a.m. ET.
In order to participate, please dial the following numbers (at least 10 minutes before the scheduled start time): United States 1-866-966-1396; Canada 1-866-992-6802 or International +44(0) 2071 928000; passcode: 44010191. For a list of other international toll-free numbers, click here.
A live webcast of the call will also be available on Tevas website at: www.ir.tevapharm.com Please log in at least 10 minutes prior to the conference call in order to download the applicable audio software.
Following the conclusion of the call, a replay of the webcast will be available within 24 hours on the Companys website. The replay can also be accessed until February 5, 2017, 9:00 a.m. ET by calling United States 1-866-247-4222; Canada 1-866-878-9237 or International +44(0) 1452550000; passcode: 44010191.
About Teva
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is a leading global pharmaceutical company that delivers high-quality, patient-centric healthcare solutions used by millions of patients every day. Headquartered in Israel, Teva is the worlds largest generic medicines producer, leveraging its portfolio of more than 1,800 molecules to produce a wide range of generic products in nearly every therapeutic area. In specialty medicines, Teva has a world-leading position in innovative treatments for disorders of the central nervous system, including pain, as well as a strong portfolio of respiratory products. Teva integrates its generics and specialty capabilities in its global research and development division to create new ways of addressing unmet patient needs by combining drug development capabilities with devices, services and technologies. Tevas net revenues in 2015 amounted to $19.7 billion. For more information, visit www.tevapharm.com.
Tevas Safe Harbor Statement under the U. S. Private SecuritiesLitigation Reform Act of 1995:
This press release contains forward-looking statements, which are based on managements current
beliefs and expectations and involve a number of known and unknown risks and uncertainties that
could cause our future results, performance or achievements to differ significantly from the
results, performance or achievements expressed or implied by such forward-looking statements.
Important factors that could cause or contribute to such differences include risks relating to: our
ability to develop and commercialize additional pharmaceutical products; competition for our
specialty products, especially Copaxone® (which faces competition from orally-administered
alternatives and existing and potential generic versions); our ability to integrate Allergan plcs
worldwide generic pharmaceuticals business (Actavis Generics) and to realize the anticipated
benefits of the acquisition (and the timing of realizing such benefits); the fact that following
the consummation of the Actavis Generics acquisition, we are dependent to a much larger extent than
previously on our generic pharmaceutical business; potential restrictions on our ability to engage
in additional transactions or incur additional indebtedness as a result of the substantial amount
of debt incurred to finance the Actavis Generics acquisition; the fact that for a period of time
following the Actavis Generics acquisition, we will have significantly less cash on hand than
previously, which could adversely affect our ability to grow; the possibility of material fines,
penalties and other sanctions and other adverse consequences arising out of our ongoing FCPA
investigations and related matters; our ability to achieve expected results from investments in our
pipeline of specialty and other products; our ability to identify and successfully bid for suitable
acquisition targets or licensing opportunities, or to consummate and integrate acquisitions; the
extent to which any manufacturing or quality control problems damage our reputation for quality
production and require costly remediation; increased government scrutiny in both the U.S.
and Europe of our patent settlement agreements; our exposure to currency fluctuations and
restrictions as well as credit risks; the effectiveness of our patents, confidentiality agreements
and other measures to protect the intellectual property rights of our specialty medicines; the
effects of reforms in healthcare regulation and pharmaceutical pricing, reimbursement and coverage;
competition for our generic products, both from other pharmaceutical companies and as a result of
increased governmental pricing pressures; governmental investigations into sales and marketing
practices, particularly for our specialty pharmaceutical products; adverse effects of political or
economic instability, major hostilities or acts of terrorism on our significant worldwide
operations; interruptions in our supply chain or problems with internal or third-party information
technology systems that adversely affect our complex manufacturing processes; significant
disruptions of our information technology systems or breaches of our data security; competition for
our specialty pharmaceutical businesses from companies with greater resources and capabilities; the
impact of continuing consolidation of our distributors and customers; decreased opportunities to
obtain U.S. market exclusivity for significant new generic products; potential liability in the
U.S., Europe and other markets for sales of generic products prior to a final resolution of
outstanding patent litigation; our potential exposure to product liability claims that are not
covered by insurance; any failure to recruit or retain key personnel, or to attract additional
executive and managerial talent; any failures to comply with complex Medicare andMedicaid reporting
and payment obligations; significant impairment charges relating to intangible assets, goodwill and
property, plant and equipment; the effects of increased leverage and our resulting reliance on
access to the capital markets; potentially significant increases in tax liabilities; the effect on
our overall effective tax rate of the termination or expiration of governmental programs or tax
benefits, or of a change in our business; variations in patent laws that may adversely affect our
ability to manufacture our products in the most efficient manner; environmental risks; and other
factors that are discussed in our Annual Report on Form 20-F for the year ended December 31,
2015 and in our other filings with the U.S. Securities and Exchange Commission (the SEC).
Forward-looking statements speak only as of the date on which they are made and we assume no
obligation to update or revise any forward-looking statements or other information contained
herein, whether as a result of new information, future events or otherwise. You are advised,
however, to consult any additional disclosures we make in our reports to the SEC on Form 6-K. Also
note that we provide a cautionary discussion of risks and uncertainties under Risk Factors in our
Annual Report on Form 20-F for the year ended December 31, 2015. These are factors that we believe
could cause our actual results to differ materially from expected results. Other factors besides
those listed could also adversely affect us. This discussion is provided as permitted by the
Private Securities Litigation Reform Act of 1995.
###
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Alvotech and Teva Announce U.S. FDA Approval of SELARSDI™ (ustekinumab-aekn), biosimilar to Stelara® (ustekinumab)
- Lantronix to Participate in the 21st Annual Craig-Hallum Institutional Investor Conference on May 29, 2024
- Manhattan Bridge Capital, Inc. Reports First Quarter Results for 2024
Create E-mail Alert Related Categories
SEC FilingsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!